Solos Endoscopy, Inc
BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 – – BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company’s MamoView® Breast Endoscopy System has shown strong growth over the past 18 months. Solos management has reported that MamoView® product sales has increased as a percentage of gross sales and in the past 18 months the company has received more than $300,000 in MamoView® orders from hospitals nationwide.
The Solos Endoscopy MammoView® Breast Endoscopy System can help give women the best prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
“Management expects sales of the MamoView® to increase in the future as more physicians are trained in the procedure,” stated Robert Segersten, President of Solos Endoscopy.
There are several teaching and research hospitals that are currently utilizing the MamoView® Breast Endoscopy System across the country. Management will be working with these teaching hospitals to collect data and identify new surgeons in an effort to increase sales.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line following its successful Audit with TUV America. Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc.
SOURCE: Solos Endoscopy, Inc.